Ignite Creation Date:
2025-12-25 @ 1:10 AM
Ignite Modification Date:
2026-01-03 @ 2:21 AM
Study NCT ID:
NCT04095793
Status:
TERMINATED
Last Update Posted:
2022-11-30
First Post:
2019-08-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}, {'id': 'D054970', 'term': 'Pure Autonomic Failure'}, {'id': 'D007024', 'term': 'Hypotension, Orthostatic'}, {'id': 'D007022', 'term': 'Hypotension'}, {'id': 'D004244', 'term': 'Dizziness'}, {'id': 'D013575', 'term': 'Syncope'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D054969', 'term': 'Primary Dysautonomias'}, {'id': 'D001342', 'term': 'Autonomic Nervous System Diseases'}, {'id': 'D054971', 'term': 'Orthostatic Intolerance'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D012678', 'term': 'Sensation Disorders'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D014474', 'term': 'Unconsciousness'}, {'id': 'D003244', 'term': 'Consciousness Disorders'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000601820', 'term': 'ampreloxetine'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'medinfo@theravance.com', 'phone': '855 633 8479', 'title': 'Medical Monitor', 'phoneExt': '+1', 'organization': 'Theravance Biopharma'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Because the study was terminated early by the Sponsor, the latest scheduled study visit completed by any participant was at Week 98.'}}, 'adverseEventsModule': {'timeFrame': 'Day 1 up to a maximum of 749 days', 'description': 'The safety set was defined as all enrolled participants who received at least 1 dose of ampreloxetine in the study.', 'eventGroups': [{'id': 'EG000', 'title': 'Ampreloxetine', 'description': 'Participants received a single dose of 10 mg ampreloxetine QD for a planned duration of up to 182 weeks.', 'otherNumAtRisk': 110, 'deathsNumAtRisk': 110, 'otherNumAffected': 24, 'seriousNumAtRisk': 110, 'deathsNumAffected': 1, 'seriousNumAffected': 14}], 'otherEvents': [{'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 6}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Benign prostatic hyperplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 4}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}], 'seriousEvents': [{'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Decubitus ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Paraparesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Prostatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 5, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Flank pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Lethargy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.1)'}], 'frequencyThreshold': '3'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Ampreloxetine', 'description': 'Participants received a single dose of 10 mg ampreloxetine QD for a planned duration of up to 182 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '61', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 up to a maximum of 749 days', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period.\n\nClinically significant abnormalities in physical and neurological examinations, vital signs, resting 12-lead electrocardiograms, and clinical laboratory evaluations, in addition to incidence of fall, suicidal ideation, and suicidal behavior, were reported as AEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety set was defined as all enrolled participants who received at least 1 dose of ampreloxetine in the study.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Ampreloxetine', 'description': 'Participants received a single dose of 10 mg ampreloxetine once daily (QD) for a planned duration of up to 182 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '110'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '110'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}]}, {'type': 'Study Terminated by Sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '103'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}]}]}], 'recruitmentDetails': 'A total of 110 participants who completed Study 0170 rolled over into Study 0171. The study was performed in Europe, Asia/Pacific, and the United States between 19 September 2019 and 12 November 2021.', 'preAssignmentDetails': 'The study was planned to consist of 3 periods: 26-week treatment,156-week treatment extension, and 2-week follow-up.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Ampreloxetine', 'description': 'Participants received a single dose of 10 mg ampreloxetine QD for a planned duration of up to 182 weeks.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '68.4', 'spread': '8.29', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '31', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '79', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '105', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '3', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '108', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Primary Diagnosis', 'classes': [{'categories': [{'title': 'Multiple System Atrophy', 'measurements': [{'value': '34', 'groupId': 'BG000'}]}, {'title': "Parkinson's Disease", 'measurements': [{'value': '58', 'groupId': 'BG000'}]}, {'title': 'Pure Autonomic Failure', 'measurements': [{'value': '18', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The safety analysis set was defined as all enrolled participants who have received at least one dose of ampreloxetine in this study.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-08-05', 'size': 1718246, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-11-07T14:03', 'hasProtocol': True}, {'date': '2022-01-13', 'size': 460203, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-11-07T14:04', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 110}}, 'statusModule': {'whyStopped': 'Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2019-09-19', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-11', 'completionDateStruct': {'date': '2021-11-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-11-07', 'studyFirstSubmitDate': '2019-08-01', 'resultsFirstSubmitDate': '2022-11-07', 'studyFirstSubmitQcDate': '2019-09-17', 'lastUpdatePostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-11-07', 'studyFirstPostDateStruct': {'date': '2019-09-19', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-11-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 1 up to a maximum of 749 days', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period.\n\nClinically significant abnormalities in physical and neurological examinations, vital signs, resting 12-lead electrocardiograms, and clinical laboratory evaluations, in addition to incidence of fall, suicidal ideation, and suicidal behavior, were reported as AEs.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Symptomatic Neurogenic Orthostatic Hypotension', 'sympomatic nOH', 'multiple symptom atrophy', 'MSA', "Parkinson's disease", 'PD', 'pure autonomic failure', 'PAF', 'orthostatic hypotension', 'OH', 'ampreloxetine', '171', 'low blood pressure', 'dizziness', 'fainting', 'blacking out', 'lightheadedness', 'norepinephrine', 'hypotension', 'OAK'], 'conditions': ['Symptomatic Neurogenic Orthostatic Hypotension']}, 'descriptionModule': {'briefSummary': 'A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.', 'detailedDescription': 'This is a Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH. The study consists of 3 periods: (i) 26-week treatment, (ii) 156-week treatment extension, and (iii) 2-week follow-up.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '30 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Completion of Study 0170 and, in the opinion of the Investigator, would benefit from long-term treatment with ampreloxetine.\n* The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).\n* The subject must be willing to continue on treatment and must continue to meet all the inclusion criteria for the preceding study (Study 0170) except, a score of \\>4 in OHSA#1.\n\nExclusion Criteria:\n\n* Subjects may not be enrolled in another clinical trial.\n* Psychiatric, neurological, or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.\n* Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant.\n* Hypersensitivity to ampreloxetine or the formulation excipients."}, 'identificationModule': {'nctId': 'NCT04095793', 'acronym': 'OAK', 'briefTitle': 'Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure', 'organization': {'class': 'INDUSTRY', 'fullName': 'Theravance Biopharma'}, 'officialTitle': 'A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure', 'orgStudyIdInfo': {'id': '0171'}, 'secondaryIdInfos': [{'id': '2019-002425-30', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ampreloxetine', 'description': 'Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.', 'interventionNames': ['Drug: ampreloxetine']}], 'interventions': [{'name': 'ampreloxetine', 'type': 'DRUG', 'otherNames': ['TD-9855'], 'description': 'Oral tablet, QD', 'armGroupLabels': ['ampreloxetine']}]}, 'contactsLocationsModule': {'locations': [{'zip': '80907', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Colorado Springs Neurological Associates', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': "Parkinson's Disease and Movement Disorders Center of Boca Raton", 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '33952', 'city': 'Port Charlotte', 'state': 'Florida', 'country': 'United States', 'facility': 'Neurostudies, Inc.', 'geoPoint': {'lat': 26.97617, 'lon': -82.09064}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60026', 'city': 'Glenview', 'state': 'Illinois', 'country': 'United States', 'facility': 'NorthShore University HealthSystem', 'geoPoint': {'lat': 42.06975, 'lon': -87.78784}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'University of Kansas Medical Center', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic - Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'New York University School of Medicine', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'University of Cincinnati Medical Center (UCGNI)', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health & Science University (OHSU)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt University Medical Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '99202', 'city': 'Spokane', 'state': 'Washington', 'country': 'United States', 'facility': 'Inland Northwest Research', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': '02139', 'city': 'Concord', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Concord Hospital, Neurosciences Department', 'geoPoint': {'lat': -33.84722, 'lon': 151.10381}}, {'zip': '3168', 'city': 'Clayton', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Clinical Trials Centre, Level 3 Monash Health Translational Precinct Building Monash Medical Centre', 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'zip': '06009', 'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Perron Institute for Neurological and Translational Science', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': '3430', 'city': 'Tulln', 'country': 'Austria', 'facility': 'Universitätsklinikum Tulln Abteilung fur Neurologie', 'geoPoint': {'lat': 48.32829, 'lon': 16.05858}}, {'zip': '1113', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MHATNP -Sv. Naum- EAD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1113', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MHATNP Sv. Naum EAD Clinic of Neurological Diseases for Locomotor Disorders', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': 'H3A 2B4', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Montreal Neurological Institute & Hospital', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '2400', 'city': 'Copenhagen', 'country': 'Denmark', 'facility': 'Bispebjerg Hospital', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '50406', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Tartu University Hospital', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '30029', 'city': 'Nîmes', 'state': 'Gard', 'country': 'France', 'facility': 'CHU de Nîmes - Hôpital Caremeau', 'geoPoint': {'lat': 43.83665, 'lon': 4.35788}}, {'zip': '7551', 'city': 'Gera', 'state': 'Thuringia', 'country': 'Germany', 'facility': 'Praxis Dr. med. Christian Oehlwein', 'geoPoint': {'lat': 50.88029, 'lon': 12.08187}}, {'zip': '13353', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite - Campus Virchow- Klinikum, Klinik fur Neurologie', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '6423906', 'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '5100', 'city': 'Terni', 'state': 'Umbria', 'country': 'Italy', 'facility': 'Ospedaliera Santa Maria Terni', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'zip': '40139', 'city': 'Bologna', 'country': 'Italy', 'facility': 'Universita di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche Ospedale Bellaria', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '40139', 'city': 'Bologna', 'country': 'Italy', 'facility': 'UO Farmacia Centralizzata OM (SC) Ospedale Maggiore', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '20122', 'city': 'Milan', 'country': 'Italy', 'facility': 'Fondazione IRCCS CA Granda Ospedale Maggiore Pliclinico - U.O. Neurologia', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '00133', 'city': 'Roma', 'country': 'Italy', 'facility': 'Fondazione PTV - Policlinico Tor Vergata I U.0.C. Neurologia', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00168', 'city': 'Roma', 'country': 'Italy', 'facility': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS / Istituto di Neurologia - Ambulatorio Disturbi del Movimento', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '84131', 'city': 'Salerno', 'country': 'Italy', 'facility': "AOU San Giovanni di Dio e Ruggi d'Aragona", 'geoPoint': {'lat': 40.67545, 'lon': 14.79328}}, {'zip': '08011', 'city': 'Christchurch', 'country': 'New Zealand', 'facility': 'New Zealand Brain Research Institute', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'zip': '40588', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Specjalistyczna Praktyka Lekarska prof.Grzegorz Opala', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '31-505', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '32-600', 'city': 'Oświęcim', 'country': 'Poland', 'facility': 'Instytut Zdrowia Dr Boczarska-Jedynak SP. Z 0.0., SP. K.', 'geoPoint': {'lat': 50.03437, 'lon': 19.21037}}, {'zip': '41-100', 'city': 'Siemianowice Śląskie', 'country': 'Poland', 'facility': 'Neuro-Care Sp. z o.o. sp. Komandytowa', 'geoPoint': {'lat': 50.32738, 'lon': 19.02901}}, {'zip': '02-793', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'ETG Warszawa', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '30-539', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Specjalistyczn.e Gabinety Sp. Z o.o.', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '2560-280', 'city': 'Torres Vedras', 'country': 'Portugal', 'facility': 'Campus Neurologico Senior', 'geoPoint': {'lat': 39.09109, 'lon': -9.2586}}, {'zip': '660037', 'city': 'Krasnoyarsk', 'country': 'Russia', 'facility': 'Federal State Budgetary Institution Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'zip': '660049', 'city': 'Krasnoyarsk', 'country': 'Russia', 'facility': 'Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'zip': '125284', 'city': 'Moscow', 'country': 'Russia', 'facility': 'SBEI APE Russian Medical Academy of Postgraduate Education of the MoH of the RF', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '630091', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Limited Liability Company City Neurological Center Sibneiromed', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '630091', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital No. 34', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '192019', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'FSBI "National Medical Research Centre of psychiatry and neurology named after V.M. Bekhterev" of the MOH of the Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '8003', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital del Mar', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '48903', 'city': 'Bilbao', 'country': 'Spain', 'facility': 'Hospital de Cruces', 'geoPoint': {'lat': 43.26271, 'lon': -2.92528}}, {'zip': '28006', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario de La Princesa', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '61172', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Municipal Instituion of Health: Kharkiv Public Outpatient Clinic 9, Kharkiv Medical Academy of Post-Graduate Education, Department of General Practice - Family Medicine', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '79010', 'city': 'Lviv', 'country': 'Ukraine', 'facility': 'Lviv Regional Clinical Hospital', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'zip': '21005', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'CNE Acad O.I. Yushchenko Vinnytsia Reg Psychoneurological Hospital of Vinnytsia Regional Council, Department of Neurology', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': 'WC1N 3BG', 'city': 'London', 'state': 'Greater London', 'country': 'United Kingdom', 'facility': 'The National Hospital for Neurology & Neurosurgery', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'W1G 9JF', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Re:Cognition Health Ltd', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Medical Monitor', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Theravance Biopharma'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Theravance Biopharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}